On September 22, 2025, Johnson Rice upgraded Johnson & Johnson (NYSE:JNJ) to a "Buy" rating, with the stock priced at $174.21. Johnson & Johnson, a global leader in pharmaceuticals, medical devices, and consumer health products, has been a staple in the healthcare industry. The company competes with other giants like Pfizer and Merck.
Johnson & Johnson has seen a remarkable increase in its market capitalization, adding $63 billion in the past three months. This growth is driven by a 17.7% rise in its share price, fueled by technical momentum and advancements in its product pipeline. The company's Innovative Medicine sales increased by 2.4%, even with the expiration of Stelara's patent.
MedTech sales have also contributed to Johnson & Johnson's growth, rising by 6.1%. This increase is supported by contributions from Abiomed, Shockwave, and new product launches. These advancements have captured investor interest, further solidifying the company's position in the market.
The stock's technical performance has been strong, consistently trading above its 50-day and 200-day moving averages since mid-June. A "golden cross" occurred in mid-July, when the 50-day moving average surpassed the 200-day moving average. This event suggests a potential for continued bullish trends, indicating positive prospects for JNJ's future stock performance.
Currently, JNJ is priced at $174.21, experiencing a slight decrease of 1.12%, with a change of $1.98. The stock has fluctuated between a low of $174.12 and a high of $176.64 today. Over the past year, JNJ has reached a high of $181.16 and a low of $140.68. The company's market capitalization is approximately $419.56 billion, with a trading volume of 4,526,431 shares.
